Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

被引:25
|
作者
Graziani, Grazia [1 ]
Ruffini, Federica [2 ]
Tentori, Lucio [1 ]
Scimeca, Manuel [3 ]
Dorio, Annalisa S. [1 ]
Atzori, Maria Grazia [1 ]
Failla, Cristina M. [4 ]
Morea, Veronica [5 ]
Bonanno, Elena [3 ]
D'Atri, Stefania [2 ]
Lacal, Pedro M. [2 ]
机构
[1] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy
[2] Ist Dermopat Immacolata IRCCS, Lab Mol Oncol, Rome, Italy
[3] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
[4] Ist Dermopat Immacolata IRCCS, Lab Expt Immunol, Rome, Italy
[5] Natl Res Council Italy CNR, Inst Mol Biol & Pathol, Rome, Italy
关键词
VEGFR-1; PlGF; melanoma; angiogenesis; monocyte/macrophage; HUMAN-MELANOMA CELLS; COLORECTAL-CANCER; CRYSTAL-STRUCTURE; BREAST-CARCINOMA; VEGF RECEPTOR-1; IN-VIVO; INHIBITION; SURVIVAL; FLT-1; BEVACIZUMAB;
D O I
10.18632/oncotarget.12108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase transmembrane receptor that has also a soluble isoform containing most of the extracellular ligand binding domain (sVEGFR-1). VEGF-A binds to both VEGFR-2 and VEGFR-1, whereas placenta growth factor (PlGF) interacts exclusively with VEGFR-1. In this study we generated an anti-VEGFR-1 mAb (D16F7) by immunizing BALB/C mice with a peptide that we had previously reported to inhibit angiogenesis and endothelial cell migration induced by PlGF. D16F7 did not affect binding of VEGF-A or PlGF to VEGFR-1, thus allowing sVEGFR-1 to act as decoy receptor for these growth factors, but it hampered receptor homodimerization and activation. D16F7 inhibited both the chemotactic response of human endothelial, myelomonocytic and melanoma cells to VEGFR-1 ligands and vasculogenic mimicry by tumor cells. Moreover, D16F7 exerted in vivo antiangiogenic effects in a matrigel plug assay. Importantly, D16F7 inhibited tumor growth and was well tolerated by B6D2F1 mice injected with syngeneic B16F10 melanoma cells. The antitumor effect was associated with melanoma cell apoptosis, vascular abnormalities and decrease of both monocyte/macrophage infiltration and myeloid progenitor mobilization. For all the above, D16F7 may be exploited in the therapy of metastatic melanoma and other tumors or pathological conditions involving VEGFR-1 activation.
引用
收藏
页码:72868 / 72885
页数:18
相关论文
共 50 条
  • [31] Vascular Endothelial Growth Factor Receptor-1 Expression in Breast Cancer and Its Correlation to Vascular Endothelial Growth Factor A
    Srabovic, Nahida
    Mujagic, Zlata
    Mujanovic-Mustedanagic, Jasminka
    Softic, Adaleta
    Muminovic, Zdeno
    Rifatbegovic, Adi
    Begic, Lejla
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2013, 2013
  • [32] Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
    Terheyden, Patrick
    Hofmann, Maja Ann
    Weininger, M.
    Broecker, Eva-B.
    Becker, Juergen C.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2007, 133 (11) : 897 - 901
  • [33] Ligand binding domains of human vascular endothelial growth factor receptor
    Ma, L
    Wang, XN
    Zhang, ZQ
    Zhou, XM
    Zeng, GF
    Chen, AJ
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2000, 32 (05): : 463 - 468
  • [34] Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
    Patrick Terheyden
    Maja Ann Hofmann
    M. Weininger
    Eva-B. Bröcker
    Jürgen C. Becker
    Journal of Cancer Research and Clinical Oncology, 2007, 133 : 897 - 901
  • [35] Expression and characterization of a novel single-chain anti-vascular endothelial growth factor antibody in the goat milk
    Leiva, Maria J.
    Parra, Natalie C.
    Contreras, Maria A.
    Tavares, Kaio C. S.
    Macaya, Luis
    Martins, Leonardo
    Gaudencio, Saul
    Hidalgo, Angela
    Kozak, Radoslaw P.
    Gonzalez, Alain
    Sanchez, Oliberto
    Toledo, Jorge R.
    Montesino, Raquel
    JOURNAL OF BIOTECHNOLOGY, 2021, 338 : 52 - 62
  • [36] Structure and function of vascular endothelial growth factor receptor-1 and -2
    Shibuya, M
    Ito, N
    Claesson-Welsh, L
    VASCULAR GROWTH FACTORS AND ANGIOGENESIS, 1999, 237 : 59 - 83
  • [37] Development of a Novel Targeted Adenovirus Vector Displaying Monobody Binding to Anti-Vascular Endothelial Growth Factor Receptor 2 in a Fiber Protein
    Matsui, Hayato
    Sakurai, Fuminori
    Tachibana, Masashi
    Kurachi, Shinnosuke
    Katayama, Kazufumi
    Mizuguchi, Hiroyuki
    MOLECULAR THERAPY, 2012, 20 : S149 - S149
  • [38] The effect of anti-vascular endothelial growth factor antibody on pleurodesis induced by transforming growth factor beta in rabbits
    Guo, Y
    Kalomemdis, I
    Hawthorn, M
    Lane, KB
    Light, RW
    CHEST, 2003, 124 (04) : 220S - 220S
  • [39] Clinical Use of Anti-Vascular Endothelial Growth Factor Monoclonal Antibodies in Metastatic Colorectal Cancer
    Chase, Judy L.
    PHARMACOTHERAPY, 2008, 28 (11): : 23S - 30S
  • [40] Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases
    Kasuya, Kazuhiko
    Suzuki, Minako
    Nagakawa, Yuichi
    Suzuki, Yoshiaki
    Kikuchi, Satoru
    Kyo, Bunso
    Matsudo, Takaaki
    Itoi, Takao
    Tsuchida, Akihiko
    Aoki, Tatsuya
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (02) : 347 - 350